Oncogenic protein interfaces: small molecules, big challenges
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein–protein interactions (PPIs) play a crucial role in numerous biological processes, including signal transduction, cell proliferation, growth, differentiation, apoptosis.303–305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“However, their suitability for tight and narrow PPI interfaces and poor selectivity limits their application in targeting PPIs.305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“PPIs have relatively large and amorphous interfaces, rather than small and well-defined crevices.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
In the citing paper
“Compared with targeting enzymes or receptors, however, the development of molecules targeting PPIs has been challenging [22–24].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 1
- Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1–9 (2011).
Cited by
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
“Such a modulator may face pharmacokinetic issues due to its large molecular weight and poor solubility.(8) Therefore, the small molecule modulator is more suitable for the tight and narrow PPI interface.”
BackgroundTherapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 611
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
“High-quality structural data of known receptor targets involved in cancer can accurately predict specific drug targets using drug libraries.(451,452) As an exemplar, bromovinyldeoxyuridine (BVDU) is a thymidine analog used for the treatment of herpes zoster infection, which interacts with viral thymidine kinase using…”
BackgroundDrugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
“This breadth has led to tremendous excitement in the drug development field, particularly with regard to targeting the “undruggable” proteome (15).”
BackgroundRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Peptide therapeutics: Targeting the undruggable space
Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2015) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 289
Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
Ran, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263
“Introduction Protein–protein interactions (PPIs) are potential drug targets for a broad range of therapeutic areas, such as oncology [1,2 ,3,4 ,5], immune-checkpoints for cancer immunotherapy [6], tropical infectious diseases [7 ], neurological disorders [8], heart failure [9] and inflammation”
BackgroundImprovements, trends, and new ideas in molecular docking: 2012–2013 in review
Yuriev, E., Holien, J., & Ramsland, P. A. (2015) · Journal of Molecular Recognition · doi:10.1002/jmr.2471 · Cited by 263
“[127] Finding druggable pockets on PPIs is also a challenging task because they tend to be more fl exible, more transient, and often do not have a known ligand.”
BackgroundSelf-citationZeng, S., Huang, W., Zheng, X., cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 245
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 216
“108,109 This can often necessitate a modulator that covers a substantial surface area and establishes numerous hydrophobic contacts, a pro fi le that frequently introduces pharmacokinetic hurdles due to the large size and poor solubility of such moleules.”
Systematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
“For example, only part of the protein target may be able to be expressed and amenable to an assay format, or multiprotein complexes and other cofactors may play a more substantial role in vivo than what is replicated in the assay [14].”
Telonis, A. G., Loher, P., Jing, Y., Londin, E., & Rigoutsos, I. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv922 · Cited by 178
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
“They are frequently developed as regulators, mainly inhibitors, of target proteins or other biomolecules (174, 303).”
BackgroundPROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., Ter Brake, F., Essa, K., & Dömling, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 163
“designing small molecules that can bind to a cavity or pocket, leading to therapeutic benefit [5].”
BackgroundState-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Interfering peptides targeting protein–protein interactions: the next generation of drugs?
Bruzzoni‐Giovanelli, H., Alezra, V., Wolff, N., Dong, C., Tufféry, P., & Rebollo, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.016 · Cited by 169
Jubb, H. C., Pandurangan, A. P., Turner, M. A., Ochoa-Montaño, B., Blundell, T. L., & Ascher, D. B. (2017) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.10.002 · Cited by 154
“PPI modulators, including smallmolecules, peptides and larger macromolecules such as antibodies, have been developed as inhibitors or stabilisers of protein complex formation and dynamics (Fischer et al., 2015; Nero et al., 2014; Watt et al., 2014).”
BackgroundSTAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061787 · Cited by 127
“Likewise, direct inhibition of STAT3 itself has proven challenging because of the high similarity with STAT1, a member mostly involved in cell death and defence against pathogens [30], and the lack of suitable docking pockets for the high-affinity binding of small molecules [31].”
BackgroundCastell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 125
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
“Importantly, we comprehensively review the recent progress in the devel- opment of allosteric modulators to inhibit or stabilize PPIs.”
BackgroundInfluentialVilloutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C., Lagorce, D., Sperandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 116
Metcalfe, R. D., Putoczki, T. L., & Griffin, M. D. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01424 · Cited by 130
“This work was supported by the National Health & Medical Research Council of Australia (APP1147621 and APP1080498) andWorldwide Cancer Research (14-1197).”
BackgroundMethodRepurposing of drugs as STAT3 inhibitors for cancer therapy
Thilakasiri, P. S., Dmello, R. S., Nero, T. L., Parker, M. W., Ernst, M., & Chand, A. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.022 · Cited by 116
Self-citationApplication of isothermal titration calorimetry as a tool to study natural product interactions
Callies, O., & Daranas, A. H. (2016) · Natural Product Reports · doi:10.1039/c5np00094g · Cited by 118
The SIX1-EYA transcriptional complex as a therapeutic target in cancer
Blevins, M. A., Towers, C. G., Patrick, A. N., Zhao, R., & Ford, H. L. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.978860 · Cited by 117
“Often, these helix-grooves can form smaller pockets more comparable to classic enzyme active sites than the flat planar surfaces of globular protein interfaces, due to their structured and well-defined clefts [89].”
BackgroundTargeting the canonical Wnt/β‐catenin pathway in hematological malignancies
Ashihara, E., Takada, T., & Maekawa, T. (2015) · Cancer Science · doi:10.1111/cas.12655 · Cited by 107
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Alternative modulation of protein–protein interactions by small molecules
Fischer, G., Rossmann, M., & Hyvönen, M. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.04.006 · Cited by 96
Thioredoxin reductase inhibitors: a patent review
Zhang, B., Zhang, J., Peng, S., Liu, R., Li, X., Hou, Y., Han, X., & Fang, J. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272576 · Cited by 103
Sable, R. V., & Jois, S. D. S. (2015) · Molecules · doi:10.3390/molecules200611569 · Cited by 99
Sang, P., Zhang, M., Shi, Y., Li, C., Abdulkadir, S., Li, Q., Ji, H., & Cai, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819663116 · Cited by 99
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 92
He, W., Wang, S., Yan, J., Qu, Y., Jin, L., Sui, F., Li, Y., You, W., Yang, G., Yang, Q., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807736 · Cited by 82
Targeting Eph/ephrin system in cancer therapy
Lodola, A., Giorgio, C., Incerti, M., Zanotti, I., & Tognolini, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.029 · Cited by 81
TEAD–YAP Interaction Inhibitors and MDM2 Binders from DNA‐Encoded Indole‐Focused Ugi Peptidomimetics
Kunig, V. B. K., Potowski, M., Akbarzadeh, M., Škopić, M. K., Smith, D. D. S., Arendt, L., Dormuth, I., Adihou, H., Andlovic, B., Karataş, H., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006280 · Cited by 87
Shen, M., Wei, Y., Kim, H., Wan, L., Jiang, Y., Hang, X., Raba, M., Remiszewski, S., Rowicki, M., Wu, C.-G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00279-5 · Cited by 90
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 79
Guo, Z., Li, B., Cheng, L.-T., Zhou, S., McCammon, J. A., & Che, J. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/ct500867u · Cited by 74
Borkin, D., Pollock, J., Kempinska, K., Purohit, T., Li, X., Wen, B., Zhao, T., Miao, H., Shukla, S., He, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01305 · Cited by 76
“2-(2-Cyano-6-methoxy-4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indol-1-yl)acetamide (26)— Similar procedure was used as for 7 but starting with 26 mg (0.”
MethodDNA-encoded libraries – an efficient small molecule discovery technology for the biomedical sciences
Kunig, V. B. K., Potowski, M., Gohla, A., & Brunschweiger, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0119 · Cited by 74
Ahmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., Memon, F. H., & Choi, K. H. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28693 · Cited by 69
“…are variety of ML and DL approaches used such as drug ‐ target interaction (DTI) prediction, 187 – 191 drug – drug interaction, 78,192,193 target – target or protein – protein interaction (PPI), 194 – 197 and drug ‐ target ‐ disease 184 for drug repurposing in cancer and other related diseases.”
MethodA unified lead-oriented synthesis of over fifty molecular scaffolds
Doveston, R. G., Tosatti, P., Dow, M., Foley, D. J., Li, H. Y., Campbell, A. J., House, D., Churcher, I., Marsden, S. P., & Nelson, A. S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02287d · Cited by 74
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 82
Integrative Modeling of Biomolecular Complexes: HADDOCKing with Cryo-Electron Microscopy Data
van Zundert, G. C. P., Melquiond, A. S. J., & Bonvin, A. M. J. J. (2015) · Structure · doi:10.1016/j.str.2015.03.014 · Cited by 71
“For a thorough and fundamental understanding of these processes and rational drug design, knowledge of these interactions and interfaces at an atomic level is of paramount importance (Wells and McClendon, 2007; Nero et al., 2014).”
BackgroundWong, N. K., Huang, C., Islam, R., & Yip, S. P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0673-6 · Cited by 73
AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein–Protein Interaction Interfaces
Rooklin, D. W., Wang, C., Katigbak, J., Arora, P. S., & Zhang, Y. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00103 · Cited by 72
DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations
Hu, J., Gao, J., Fang, X., Liu, Z., Wang, F., Huang, W., Wu, H., & Zhao, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac302 · Cited by 65
Borkin, D., Klossowski, S., Pollock, J., Miao, H., Linhares, B. M., Kempinska, K., Jin, Z., Purohit, T., Wen, B., He, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00071 · Cited by 63
“Furthermore, compounds 24-27 demonstrate good microsomal stability, with the sulfonyl (26) or sulfonamide (27) analogues exhibiting the longest half-life in mouse liver microsomes (T1/2 > 60 min).”
BackgroundMethodBlakskjær, P., Heitner, T., & Hansen, N. J. V. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.02.003 · Cited by 64
“com Hits discovered by screening DNA-encoded chemical libraries The power and versatility of DELs have been demonstrated by the identification of inhibitors towards both enzyme targets [30,36,50,51] and more challenging targets such as PPI targets [25 ,52].”
BackgroundLiao, G., Yang, D., Ma, L., Li, W., Hu, L., Zeng, L., Wu, P., Duan, L., & Liu, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.044 · Cited by 63
Luchini, A., Espina, V., & Liotta, L. A. (2014) · Nature Communications · doi:10.1038/ncomms5413 · Cited by 62
“Resulting antibodies were qualified with (1) solid phase ELISA against Arg286 peptide and selected if they had an ELISA titre higher than 1:100,000, and (2) western blotting and selected if they showed single band reactivity with the IL1RAcP protein (Novoprotein).”
MethodKuenemann, M. A., Spérandio, O., Labbé, C. M., Lagorce, D., Miteva, M. A., & Villoutreix, B. O. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.006 · Cited by 64
Computational approaches for the design of modulators targeting protein-protein interactions
Rehman, A. U., Khurshid, B., Ali, Y., Rasheed, S., Wadood, A., Ng, H. L., Chen, H., Wei, Z., Luo, R., & Zhang, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2171396 · Cited by 68
“…over 50 PPIs, with >27 already in Phase I, II, and III clinical trials, primarily involving viral, autoimmune diseases, and cancer [5] So far, the FDA has approved ~5 PPI modulators to treat cancer, dry eye syndrome, autoimmune diseases, and disorders that do not respond to other treatments [5–7].”
BackgroundApplication of Fragment‐Based Screening to the Design of Inhibitors of Escherichia coli DsbA
Adams, L. A., Sharma, P., Mohanty, B., Ilyichova, O. V., Mulcair, M. D., Williams, M. L., Gleeson, E. C., Totsika, M., Doak, B. C., Caria, S., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201410341 · Cited by 59
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance
Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 64
Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 62
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Cossar, P. J., Lewis, P. J., & McCluskey, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21519 · Cited by 55
Rakers, C., Bermudez, M., Keller, B. G., Mortier, J., & Wolber, G. (2015) · WIREs Computational Molecular Science · doi:10.1002/wcms.1222 · Cited by 55
Application of Thiol–yne/Thiol–ene Reactions for Peptide and Protein Macrocyclizations
Wang, Y., Bruno, B. J., Cornillie, S. P., Nogieira, J. M., Chen, D., Cheatham, T. E., Lim, C. S., & Chou, D. H. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201700572 · Cited by 60
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
“1A) currently in clinical trials for lymphoid malignancies (22, 72, 73).”
BackgroundInfluentialStucchi, M., Grazioso, G., Lammi, C., Manara, S., Zanoni, C., Arnoldi, A., Lesma, G., & Silvani, A. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01642a · Cited by 50
Structure-based inhibition of protein–protein interactions
Watkins, A. M., & Arora, P. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.047 · Cited by 64
Ivanov, A. A., Revennaugh, B., Rusnak, L., González-Pecchi, V., Mo, X., Johns, M. A., Du, Y., Cooper, L., Moreno, C. S., Khuri, F. R., et al. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx743 · Cited by 53
He, W., Yan, J., Sui, F., Wang, S., Su, X., Qu, Y., Yang, Q., Guo, H., Ji, M., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b07079 · Cited by 54
Singh, N., Decroly, É., Khatib, A., & Villoutreix, B. O. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105495 · Cited by 51
“, 2020) within the top 50-1000 scores, however, docking molecules into more solvent-exposed exosites, is more challenging (Bienstock, 2012; Kruger et al., 2012; Nero et al., 2014; Perot et al., 2010; Trisciuzzi et al., 2019; Villoutreix et al., 2014).”
Nim, S., O’Hara, D. M., Corbi‐Verge, C., Perez‐Riba, A., Fujisawa, K., Kapadia, M., Chau, H., Albanese, F., Pawar, G. N., de Snoo, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37464-2 · Cited by 54
Allosteric modulation of a human protein kinase with monobodies
Zorba, A., Nguyen, V., Koide, A., Hoemberger, M., Zheng, Y., Kutter, S., Kim, C., Koide, S., & Kern, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906024116 · Cited by 47
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Magnez, R., Bailly, C., & Thuru, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147672 · Cited by 56
Wiedmann, M. M., Tan, Y. S., Wu, Y., Aibara, S., Xu, W., Sore, H. F., Verma, C. S., Itzhaki, L. S., Stewart, M., Brenton, J. D., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201609427 · Cited by 46
Targeting protein-protein interaction interfaces in COVID-19 drug discovery
Chang, C., Lin, S., Satange, R., Lin, S., Sun, S.-C., Wu, H., Kehn‐Hall, K., & Hou, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.003 · Cited by 48
“Although the mechanism of action of the two drugs were elucidated long after they were approved for medical use, recent studies have proven the possibility of targeting PPIs a priori for development of new treatments against refractory diseases [32–34].”
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 47
Scanning Protein Surfaces with DNA‐Encoded Libraries
Kunig, V. B. K., Potowski, M., Škopić, M. K., & Brunschweiger, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000869 · Cited by 54
Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1
Beekman, A. M., & Howell, L. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500497 · Cited by 45
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 45
Scopy: an integrated negative design python library for desirable HTS/VS database design
Yang, Z., Yang, Z., Lü, A., Hou, T., & Cao, D. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa194 · Cited by 43
Intracellular Generation of a Diterpene-Peptide Conjugate that Inhibits 14-3-3-Mediated Interactions
Parvatkar, P. T., Kato, N., Uesugi, M., Sato, S., & Ohkanda, J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09817 · Cited by 42
Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics
He, W., Yan, J., Li, Y., Yan, S., Wang, S., Hou, P., & Lu, W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.041 · Cited by 46
TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer
Saldías, M. P., Maureira, D., Orellana‐Serradell, O., Silva, I., Lavanderos, B. J., Cruz, P., Torres, C., Cáceres, M., & Cerda, O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621614 · Cited by 51
Linear Aliphatic Dialkynes as Alternative Linkers for Double‐Click Stapling of p53‐Derived Peptides
Lau, Y. H., de Andrade, P., McKenzie, G. J., Venkitaraman, A. R., & Spring, D. R. (2014) · ChemBioChem · doi:10.1002/cbic.201402374 · Cited by 44
Zhang, X., Betzi, S., Morelli, X., & Roche, P. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.57 · Cited by 44
Therapeutic potential of targeting the Eph/ephrin signaling complex
Saha, N., Tzvetkova‐Robev, D., Mason, E. O., Himanen, J. P., & Nikolov, D. B. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.10.006 · Cited by 43
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs)
Qiu, Y., Li, X., He, X., Pu, J., Zhang, J., & Lu, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112764 · Cited by 45
A structural view of PA2G4 isoforms with opposing functions in cancer
Stevenson, B. W., Gorman, M. A., Koach, J., Cheung, B. B., Marshall, G. M., Parker, M. W., & Holien, J. K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014293 · Cited by 45
“In this review, we have highlighted the multiple protein-protein interaction sites that may be targeted by small-molecule therapeutics (73).”
BackgroundSelf-citationPooled screening for antiproliferative inhibitors of protein-protein interactions
Nim, S., Jeon, J., Corbi‐Verge, C., Seo, M., Ivarsson, Y., Moffat, J., Tarasova, N. I., & Kim, P. M. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2026 · Cited by 48
“Recently, inhibitors against a number of PPIs have emerged as candidates for new anti-cancer drugs 6 , with notable examples being the inhibitors to the Bcl2-BH3 interaction 7, 8 and the p53-MDM2 interaction 9–12 .”
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Role of the Axonal Initial Segment in Psychiatric Disorders: Function, Dysfunction, and Intervention
Hsu, J. W.-C., Nilsson, C. L., & Laezza, F. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00109 · Cited by 43
Cheng, J., Zhou, J., Kong, L., Wang, H., Zhang, Y., Wang, X., Liu, G., & Chu, Q. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00487b · Cited by 42
PPI-HotspotDB: Database of Protein–Protein Interaction Hot Spots
Chen, Y. C., Chen, Y., Wright, J. D., & Lim, C. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00025 · Cited by 39
Kumar, V., Lakshman, P. K. C., Prasad, T. K., Manjunath, K., Bairy, S. G., Vasu, A. S., Ganavi, B., Jasti, S., & Kamariah, N. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23864 · Cited by 50
“However, probing PPIs with small-molecule inhibitors or stabilizers is often difficult due to large and shallow binding interfaces, because of which PPIs are classically recognized as “ undruggable ” [151].”
BackgroundProtein structure and computational drug discovery
Nero, T. L., Parker, M. W., & Morton, C. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180202 · Cited by 42
Self-citationYeh, J., & Frank, D. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500482 · Cited by 39
Allosteric Modulators of Protein–Protein Interactions (PPIs)
Ni, D., Liu, N., & Sheng, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_13 · Cited by 38
Targeting the Ubiquitin System in Glioblastoma
Scholz, N., Kurian, K. M., Siebzehnrübl, F. A., & Licchesi, J. D. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574011 · Cited by 37
Metadata
- Authors
- Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W.
- Affiliations
- Australian Cancer Research Foundation (AU)
- The University of Melbourne (AU)
- Corresponding author
- Parker, Michael W.
- Venue
- Nature Reviews Cancer
- Published
- 2014-03-13
- Volume
- 14
- Issue
- 4
- Pages
- 248-262
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2003516462
- Cited by
- 312
- References
- 161
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 35 · 2023: 29 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 19 · 2018: 26 · 2017: 24 · 2016: 34 · 2015: 37 · 2014: 15
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, oncoprotein, small molecule modulators, drug discovery, undruggable targets, protein-protein interaction surfaces, cancer drug targets
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Drug Screening Assays, Antitumor, Humans, Neoplasms, Protein Binding, Surface Properties, Oncogene Proteins, Protein Interaction Domains and Motifs, Protein Interaction Maps, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.